| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Total revenue | ||||||
3,498 | 2,946 | 3,211 | - | - | - | |
Product sales | ||||||
- | - | - | 3,524 | 2,701 | 1,236 | |
Laboratory services | ||||||
- | - | - | 228 | 120 | 478 | |
Collaboration revenue | ||||||
- | - | - | 272 | 336 | 2,411 | |
Total revenue | ||||||
- | - | - | 4,025 | 3,157 | 4,126 | |
Operating expenses | ||||||
Cost of products sold | ||||||
- | - | - | 1,658 | 1,179 | 425 | |
Cost of services | ||||||
- | - | - | 631 | 367 | 526 | |
Research and development | ||||||
5,121 | 5,677 | 6,883 | 8,613 | 6,002 | 4,368 | |
General and administrative | ||||||
6,252 | 7,069 | 6,692 | 6,602 | 5,834 | 2,312 | |
Sales and marketing | ||||||
1,464 | 1,531 | 2,767 | 5,529 | 4,305 | 2,058 | |
Transaction costs | ||||||
779 | 0 | - | - | - | - | |
Impairment of right-of-use asset | ||||||
520 | 0 | - | - | - | - | |
Transaction expenses | ||||||
- | - | - | - | 526 | 0 | |
Total operating expenses | ||||||
15,769 | 16,126 | 18,476 | 23,035 | 18,216 | - | |
Total operating expenses | ||||||
- | - | - | - | - | 9,691 | |
Operating loss | ||||||
-12,271 | -13,180 | -15,265 | -19,009 | -15,059 | -5,564 | |
Other income (expense) | ||||||
Interest and other income | ||||||
- | - | - | - | - | 0 | |
Interest and other income (expense) | ||||||
9 | 5 | -87 | -5 | 26 | - | |
Interest expense | ||||||
187 | 191 | 233 | 143 | 1,801 | 111 | |
Foreign currency transaction losses | ||||||
2 | -10 | 23 | -8 | 0 | - | |
Change in fair value of derivative financial instruments | ||||||
0 | 8 | 144 | 0 | -647 | - | |
Change in fair value of derivative financial instruments and other | ||||||
- | - | - | - | - | 4 | |
Total other income (expense) | ||||||
-175 | -187 | -153 | -157 | -2,422 | -106 | |
Loss before income taxes | ||||||
-12,446 | -13,368 | -15,419 | -19,166 | -17,481 | -5,671 | |
Provision for income taxes | ||||||
0 | 0 | 0 | 0 | -129 | 0 | |
Net loss | ||||||
-12,446 | -13,368 | -15,419 | -19,166 | -17,352 | -5,671 | |
Preferred stock dividends and beneficial conversion | ||||||
- | - | - | 332 | 243 | - | |
Accretion of Series A preferred stock | ||||||
- | - | - | - | - | 627 | |
Net loss available to common stockholders | ||||||
- | - | - | -19,499 | -17,595 | -6,298 | |
Net loss per common share - basic and diluted | ||||||
-7.70 | -44.49 | -9.80 | -27.59 | -55.00 | -16.25 | |
Weighted average shares outstanding - basic and diluted | ||||||
1,616 | 300 | 1,573 | 706 | 319 | 387 | |
Net loss | ||||||
-12,446 | -13,368 | -15,419 | -19,166 | -17,352 | -5,671 | |
Other comprehensive income - foreign currency translations | ||||||
-4 | 12 | -32 | 7 | -1 | 0 | |
Comprehensive loss | ||||||
-12,450 | -13,355 | -15,451 | -19,159 | -17,353 | -5,671 | |
Product sales [Member] | ||||||
Total revenue | ||||||
2,168 | 2,395 | 2,771 | - | - | - | |
Cost of products and services | ||||||
911 | 1,222 | 1,612 | - | - | - | |
Laboratory Service Revenue [Member] | ||||||
Total revenue | ||||||
5 | 34 | 41 | - | - | - | |
Collaborations Revenue [Member] | ||||||
Total revenue | ||||||
1,325 | 516 | 397 | - | - | - | |
Service [Member] | ||||||
Cost of products and services | ||||||
720 | 625 | 520 | - | - | - | |